Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
STERIS plc (NYSE: STE) is a leading global provider of infection prevention and procedural surgical products and services, primarily serving healthcare, pharmaceutical, research, and medical device customers. With a mission to create a healthier today and a safer tomorrow, the company delivers innovative infection prevention, decontamination, and health science technologies that support patient care and safety.
Founded in 1985 as Innovative Medical Technologies and rebranded as STERIS in 1987, the company’s history traces back to 1894 with the American Sterilizer Company, a pioneer in sterilization products. Today, STERIS is headquartered in Dublin, Ireland, and has positioned itself as a formidable force in the industry through strategic acquisitions and continuous innovation.
STERIS operates through several segments:
- Healthcare Services: Constituting approximately 70% of total revenue, this segment includes sterilizers, washer-disinfectors, and other decontamination equipment for healthcare facilities and biopharmaceutical manufacturing sites.
- Applied Sterilization Technologies (AST): Generating 19% of revenue, AST provides contract sterilization services for single-use and implantable medical devices globally.
- Life Sciences Services: Accounting for about 11% of revenue, this segment offers services and products for research and pharmaceutical environments.
In recent developments, STERIS has signed a definitive agreement to acquire surgical and sterilization assets from Becton, Dickinson and Company (BD) for $540 million. This acquisition, expected to close by September 2023, will expand STERIS’s product offerings within its Healthcare segment, focusing on operating rooms and sterile processing departments.
Financially, STERIS has demonstrated robust growth. For the first quarter of fiscal 2024, revenue increased by 11% to $1.28 billion, driven by improvements in procedure volumes and easing of supply chain challenges. The company continues to show strength across its segments, particularly in Healthcare, which saw a 17% growth in revenue to $818.9 million.
Moreover, STERIS is undergoing a targeted restructuring plan in its Healthcare surgical business in Europe, aiming to enhance its operational efficiency. This includes product rationalizations and facility consolidations, signaling a commitment to long-term profitability and growth.
STERIS remains committed to its vision of creating a safer world through continuous innovation and strategic expansions, making it a key player in the global healthcare industry.
STERIS (NYSE: STE) reported strong financial results for Q3 FY2025. Total revenue from continuing operations increased 6% to $1.4 billion, with constant currency organic revenue also growing 6%. Net income reached $173.6 million ($1.75 per diluted share), up from $148.4 million in Q3 FY2024. Adjusted net income was $229.1 million ($2.32 per diluted share).
Healthcare revenue grew 7% to $976.0 million, while Applied Sterilization Technologies revenue increased 10% to $258.1 million. Life Sciences revenue decreased 7% to $136.4 million. Free cash flow for the first nine months reached $588.1 million, up from $457.0 million.
The company updated its FY2025 outlook, now expecting revenue growth of approximately 6%, down from previous guidance of 6.5-7.5%, primarily due to currency impacts and lower Healthcare capital equipment revenue. Adjusted EPS guidance was revised to $9.05-$9.15.
STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.57 per share. The dividend will be paid on March 21, 2025, to shareholders who are on record at the close of business on February 20, 2025.
STERIS, a leading global provider of products and services focused on infection prevention, supports patient care and helps customers create a healthier and safer world through innovative healthcare and life sciences solutions globally.
STERIS (NYSE: STE) has announced it will host a conference call on February 6, 2025, at 9:00 a.m. ET to discuss its fiscal 2025 third quarter financial results. The company will release its financial results press release after U.S. market closure on February 5, 2025.
Investors can access the live conference call through www.steris-ir.com or by phone using 1-833-535-2199 (U.S.) or 1-412-902-6776 (International). A replay will be available from 12:00 p.m. ET on February 6, using access code 2513153, accessible via the company website or by calling 1-877-344-7529 (U.S.) or 1-412-317-0088 (International).
STERIS plc (NYSE: STE) announced that a jury trial against its subsidiary Isomedix Operations ended in a mistrial on January 17, 2025. The trial, which began on December 4, 2024, involved claims that ethylene oxide emissions from a Waukegan, Illinois sterilization facility caused personal injury. Isomedix operated the facility from 2005 to 2008.
The mistrial was declared at the plaintiff's request during jury deliberations when the dismissal of a juror reduced the jury count below twelve. The case, pending in the Circuit Court of Cook County, Illinois, will be scheduled for re-trial. Isomedix maintains its commitment to defending against allegations regarding its ethylene oxide operations and emissions, stating it has invested in facilities and implemented processes that meet or exceed environmental regulatory standards.
STERIS reported strong fiscal 2025 second quarter results with total revenue increasing 7% to $1.3 billion. Net income reached $150.2 million ($1.51 per share), up from $119.8 million in the previous year. Healthcare revenue grew 9% to $944.2 million, while Applied Sterilization Technologies revenue increased 9% to $256.7 million. Life Sciences revenue decreased 4% to $127.9 million. The company maintained its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted earnings per share of $9.05-$9.25.
STERIS (NYSE: STE) has announced a quarterly interim dividend of $0.57 per share, payable on December 19, 2024. Shareholders of record at the close of business on November 19, 2024 will be eligible for this distribution. The company, a global leader in infection prevention products and services for healthcare and life sciences, provides additional information about U.S. tax treatment of dividends on their investor relations website.
STERIS plc (NYSE: STE) announced it will host a conference call on November 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 second quarter financial results. The company will release its financial results after market close on November 6, 2024. Investors can access the call through the company's website or by phone. A replay will be available from 12:00 p.m. ET on November 7, using access code 6859931.
STERIS plc (NYSE: STE) has announced its participation in the Morgan Stanley Healthcare Conference on September 4, 2024, in New York City. Dan Carestio, President and CEO of STERIS, will present at 1:50 p.m. Eastern Time.
The presentation will be simultaneously webcast and available for replay on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products and services supporting patient care, with a focus on infection prevention.
The company's mission is to help customers create a healthier and safer world by offering innovative healthcare and life sciences solutions globally. For further information, investors can contact Julie Winter, Vice President of Investor Relations and Corporate Communications.
STERIS plc (NYSE: STE) reported strong financial results for Q1 fiscal 2025. Total revenue from continuing operations increased 8% to $1.3 billion, with constant currency organic revenue growing 6%. As reported EPS from continuing operations rose to $1.41, while adjusted EPS increased to $2.03.
Healthcare revenue grew 10% to $901.2 million, driven by 23% growth in consumables and 14% in services. Applied Sterilization Technologies revenue increased 7% to $249.8 million. Life Sciences revenue decreased 2% to $128.5 million due to a divestiture.
The company reiterated its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted EPS of $9.05-$9.25. STERIS remains confident in delivering on its full-year guidance.
STERIS plc (NYSE: STE) has announced a 5.6% increase in its quarterly dividend to $0.57 per share, marking the company's 19th consecutive year of dividend growth. The dividend will be payable on September 20, 2024, to shareholders of record as of September 5, 2024. This represents a $0.05 increase from the previous dividend.
STERIS, a global leader in infection prevention products and services for healthcare and life sciences, continues to demonstrate its commitment to shareholder value through consistent dividend growth. The company's focus on creating a healthier and safer world through innovative solutions underscores its strong market position and financial stability.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
What does STERIS plc specialize in?
Where is STERIS plc headquartered?
What are the main business segments of STERIS plc?
How much of STERIS’s revenue comes from Healthcare Services?
What recent acquisition has STERIS plc announced?
What was STERIS’s revenue growth in the first quarter of fiscal 2024?
What is the anticipated revenue growth for fiscal 2024?
What restructuring efforts is STERIS undertaking?
What percentage of STERIS’s revenue is derived from Applied Sterilization Technologies (AST)?
When was STERIS plc originally founded?
